In this webinar, CEO David Solomon and CFO Luke Cairns review the Company’s interim results for the six months ended 30 June 2026 and progress across the RNA therapeutics portfolio.
Your question will be sent privately to Thalia Therapeutics. The company may choose to make this question public.
Start the conversation
Ask Thalia Therapeutics a question about this update.
